About
Pricing
FAQs
Providers
Trials
Blog
Login
Get started
Finding studies
Search
Narrow
Order
Status
Recruiting
Not yet recruiting
Active, not recruiting
Enrolling by invitation
Completed
Terminated
Phase
Early phase 1
Phase 1
Phase 1–2
Phase 2
Phase 2–3
Phase 3
Phase 4
No phase
Who can join
Healthy volunteers too
Searching
1–20 of 65
Recruiting
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.
NCT05379985
·
Orange, California and 20 others
Completed
AZD2171 and Temsirolimus in Patients With Advanced Gynecological Malignancies
The purpose of this research study is to determine the safety of the combination of the two drugs cediranib and temsirolimus and the highest doses of these two drugs that can be…
NCT01065662
·
Boston, Massachusetts and 2 others
Completed
Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer
Phase 1 study to evaluate the safety and tolerability of selinexor and determine the Recommended Phase 2 Dose (RP2D) of selinexor for advanced or metastatic solid tumor…
NCT01607905
·
Tampa, Florida and 5 others
Recruiting
A Phase I Clinical Trial of CAR-T Cells for Advanced Gynecological Solid Tumors
Screening patients who meet the criteria for peripheral blood mononuclear cell (PBMC) isolation and cell preparation.
NCT06904131
·
Shanghai, Shanghai Municipality
Recruiting
Study to Assess the Safety and Effects of Porphysome Nanoparticles for Imaging in Gynaecological Cancers
This is an open-label, first-in-human, dose escalation study evaluating investigational drug PORPHYSOSMES (PS, pegylated porphyrin-lipid conjugate-containing nanoparticle…
NCT06977126
·
Toronto, Ontario
Terminated
PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer
The purpose of this research study is to evaluate safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the investigational drug PLX2853 in Advanced Gynecological…
NCT04493619
·
Chicago, Illinois and 8 others
Completed
Treating Patients With Advanced Solid Tumors, Breast Cancer or Recurrent Ovarian Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
NCT00005807
·
New York, New York and 1 other
Terminated
Study to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT2003 Versus Placebo
The purpose of the study is to evaluate the efficacy and the safety of AMT2003 in cancer patients with advanced disease.
NCT00332280
·
Sarajevo and 1 other
Temporarily not available
Expanded Access of Vigil in Solid Tumors
This is an expanded access study involving an investigational product named Vigil. Vigil is considered immunotherapy.
NCT03842865
·
Dallas, Texas
Unknown
Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors
Phase II multi-chort, adaptive two-stage, open label, nonrandomized study.
NCT03827837
·
Shanghai, Shanghai Municipality
Withdrawn
Genomic and Proteomic Profiling Targets Influenced Treatment in Metastatic Breast Cancer
The primary objective is to examine the impact on progression-free survival of targeted therapy for breast cancer suggested by proteomic and genomic profiling.
NCT02470819
·
Sioux Falls, South Dakota
Terminated
Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers
Evaluate safety and tolerability, while establishing the recommended dose of the investigational drug combination of adagrasib and olaparib that can be given to participants with…
NCT06130254
·
Houston, Texas
Active not recruiting
Optimize the Support of Patients in Pelvic Onco-gynecology Through Adapted Support Care in the Post-cancer Period. AFTERGYN Pilot Phase
While the sequelae and toxicities after ovarian and endometrial cancer treatments are well described in the literature, the actual needs of patients for supportive oncology care…
NCT05731661
·
Caen
Completed
Advanced MRI Sequences for Radiation Therapy Treatment Planning
The purpose of this study is to determine if it would be helpful to use advanced MRI imaging techniques to take additional views of the tumor target for radiation treatment…
NCT02340715
·
Milwaukee, Wisconsin
Recruiting
Gut Microbiome and Treatment for Gynecological Cancer Patients Receiving Immunotherapy
30 participants with advanced or recurrent gynecological cancer from are enrolled for this study.
NCT04957511
·
Orlando, Florida
Not yet recruiting
Benefits of Early Collaboration Between Oncologists and Palliative Care Physicians in Cases of Unplanned Hospitalization for Patients With Metastatic Cancer
This is a multicenter, national, interventional, cluster-randomized study, "stepped wedge" design.
NCT07490106
·
Lille
Recruiting
A Study of SKB518 as Monotherapy or Combination Therapy in Patients With Advanced Gynecological Malignant Tumors
This is an open-label, multicenter, Phase II clinical study to evaluate the efficacy and safety of SKB518 as monotherapy or combination therapy in patients with advanced…
NCT07448922
·
Chongqing and 1 other
Completed
Early Post-Operative Enteral Feeding in Patients With Advanced Epithelial Ovarian Cancer
Ovarian cancer patients are often at risk of malnutrition because of weight loss, lack of appetite and reduced food intake.
NCT00850772
·
Auchenflower, Queensland and 5 others
Completed
The Mediating Effects of Decentering on Self-Management of Stress and End of Life Planning
Caregivers of persons with cancer may face many challenges as they support and care for a person receiving treatment.
NCT02842047
·
Cleveland, Ohio
Completed
Image-Guided Gynecologic Brachytherapy
Standard therapy for gynecologic cancers involves the use of brachytherapy, also called internal radiation therapy or implant radiation.
NCT01399658
·
Boston, Massachusetts
Back
1
2
3
4
1 / 4
Next
Data from
ClinicalTrials.gov
Terms
